Phase II Study of TAK228 in Relapsed Lymphoma
Phase of Trial: Phase II
Latest Information Update: 25 Aug 2017
At a glance
- Drugs Sapanisertib (Primary)
- Indications B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 02 Mar 2017 Planned primary completion date changed from 1 Dec 2021 to 1 Mar 2022.
- 02 Mar 2017 Status changed from not yet recruiting to recruiting.
- 26 Oct 2016 Planned primary completion date changed from 1 Aug 2021 to 1 Dec 2021.